Vertex Pharmaceuticals Incorporated reported unaudited consolidated earnings results for the fourth quarter and year ended Dec. 31, 2014. For the quarter, the company reported total revenues of $144,556,000 compared to $351,157,000 a year ago. Loss from operations was $153,625,000 compared to $10,281,000 a year ago. Loss from continuing operations was $180,637,000 or $0.74 per basic and diluted share compared to $20,920,000 or $0.09 per basic and diluted share a year ago. Net loss attributable to the company was $176,656,000 or $0.74 per basic and diluted share compared to net income attributable to the company of $44,285,000 or $0.19 per basic and diluted share a year ago. Non-GAAP net loss attributable to the company was $131,832,000 or $0.55 per basic and diluted share compared to $128,446,000 or $0.56 per basic and diluted share a year ago. Non-GAAP total revenues were $140,588,000 compared to $168,761,000 a year ago.

For the year, the company reported total revenues of $580,415,000 compared to $1,211,975,000 a year ago. Loss from operations was $692,412,000 compared to $610,008,000 a year ago. Loss from continuing operations was $741,833,000 or $3.14 per basic and diluted share compared to $503,622,000 or $2.24 per basic and diluted share a year ago. Net loss attributable to the company was $738,555,000 or $3.14 per basic and diluted share compared to $445,028,000 or $1.98 per basic and diluted share a year ago. Non-GAAP net loss attributable to the company was $511,218,000 or $2.17 per basic and diluted share compared to $203,302,000 or $0.90 per basic and diluted share a year ago. Non-GAAP total revenues were $535,789,000 compared to $1,029,579,000 a year ago.